While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

The appeal court set Empire Company Limited et al v. Attorney General of Canada, A-192-24 on Feb. 12, Wednesday. This appeal ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

Prolia made $2.3 billion in sales for Amgen last year but is a few years away from patent expiry, putting it at risk of biosimilar competition. Evenity works in a different way to Prolia ...

“Amgen seeks to monopolise an entire class ... Both drugs are facing competition from other PCSK9-targeting drugs, including Novartis’ injectable Leqvio (inclisiran), which requires less ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...